Medindia
Medindia LOGIN REGISTER
Advertisement

TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD.

Thursday, April 5, 2018 General News
Advertisement

______________________

1

Public Health Agency of Canada: Chronic Diseases Link here

2

Canadian Institute for Health Information: A Snapshot of Health Care in Canada as demonstrated by Top 10 List. P.6. Available here.

3

Statistics Canada. Leading Cause of Death by Sex.http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/hlth36a-eng.htm

4

N. Mittmann et. Al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Available here.

5

Canadian Lung Association. COPD Signs & Symptoms. Available here. 

6

Soler-Cataluna, JJ, et al. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60, 925-931.

7

Cote, CG, Dordelly, LJ, Celli, BR (2007) Impact of COPD exacerbations on patient-centered outcomes. Chest, 131(3); 696-704

8

Rennard S, Decramer Et al. Impact of COPD in North America and Europe in 2000: Subjects' perspective of confronting COPD International Survey. European Respiratory Journal. 2002:20 799-805.

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close